Pevion Biotech hires new ceo
Also secures CHF10m of financing
Prior to joining Pevion, Kueppers was ceo of Pieris, a Munich-based biotechnology company, which he successfully restructured and refinanced, raising a total US$45m. Before joining the biotech industry, he spent several years in the International Operations of BASF Pharma (now Abbott Labs) and was a management consultant with the global healthcare team of AT Kearney in London.
The company has also secured further financing of CHF10m from its existing investors, BZ Bank, BB Biotech Ventures and Core Capital.
Pevion says it plans to raise additional financing over the next 12 months to broaden its pipeline.
‘Pevion has reached an important stage in its development as its candidate products reach for critical milestones. This financing commitment should take the company a long way towards achieving further product validation,’ said Joseph Manko of BZ Bank and member of the Board of Directors.
You may also like
Regulatory
NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Research & Development
Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions
Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster